Related Experiment Videos
Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype
G I Russell1, R F Bing, J A Jones
1Department of Medicine, Leicester Royal Infirmary.
The Quarterly Journal of Medicine
|October 1, 1987
Summary
Hydralazine can cause drug-induced lupus, particularly in women with slow acetylator genes and the HLA-DR4 phenotype. Early detection is crucial as symptoms may appear years into treatment.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Hydralazine is a vasodilator used to treat hypertension.
- Drug-induced lupus erythematosus (DILE) is a known adverse effect of certain medications, including hydralazine.
Observation:
- This study describes 20 patients with hydralazine-induced systemic lupus erythematosus (SLE).
- Key clinical features, autoantibody profiles, and patient phenotypes (acetylator status, HLA-DR) were analyzed.
Findings:
- Hydralazine sensitivity was more prevalent in women, slow acetylators, and individuals with the HLA-DR4 phenotype.
- Symptoms, predominantly joint issues, can manifest even after prolonged hydralazine use.
- Early detection is vital, as no dose is considered entirely safe, even in rapid acetylators.
Implications:
- Clinicians should maintain high awareness for hydralazine-induced SLE in patients on long-term therapy.
- Discontinuation of hydralazine typically leads to symptom resolution.
- Persistent symptoms warrant investigation for alternative underlying causes of arthritis.